ARTICLE | Finance

Regulatory Milestones

Highlights of weekly biotech stock moves

August 9, 2010 7:00 AM UTC

Allergan Inc. (NYSE:AGN) was up $3.70 to $64.76 last week after the EC approved an MAA for Ozurdex dexamethasone intravitreal implant to treat macular edema following retinal vein occlusion. Allergan plans to launch the biodegradable implant in Europe this quarter.

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) was off $0.79 to $9.10 on the week after it and partner Genzyme Corp. (NASDAQ:GENZ) reported that mipomersen met the primary endpoint of significantly greater reductions in LDL-C from baseline to week 28 vs. placebo in a pair of Phase III trials in patients with hypercholesterolemia, but also showed a high drop out rate in treated patients...